mProX™ Human CCDC6 Stable Cell Line

Zhou, Yuanyuan. et al. "Performance of multigene testing in cytologically indeterminate thyroid nodules and molecular risk stratification." PeerJ, 2023.
Thyroid cancer ranks as the third most common form of cancer in women, creating a pressing need for improved diagnostic methods. To address this, researchers crafted a custom multigene testing panel and assessed its effectiveness in 529 thyroid nodules with uncertain cytological findings (Bethesda III, IV, and V). By analyzing molecular data from fine needle aspiration samples alongside clinical diagnoses and surgical outcomes, the study aimed to enhance the accuracy of malignancy prediction. The findings demonstrated a substantial overall agreement (Kappa = 0.726) with 97.80% sensitivity, 82.14% specificity, 98.99% positive predictive value, and 67.65% negative predictive value. Notably, the study identified prevalent genetic abnormalities, such as BRAFV600E (82.59%) and NRAS mutants (4.07%). Additionally, the research revealed potential links between certain molecular alterations and aggressive tumor characteristics. Ultimately, this investigation presented a valuable multigene panel for distinguishing benign from uncertain thyroid nodules, reducing unnecessary surgeries, and highlighted the potential of molecular risk stratification in predicting disease outcomes, while acknowledging the study's limitations due to the cohort's high cancer prevalence.
Zhou, Yuanyuan. et al. "Performance of multigene testing in cytologically indeterminate thyroid nodules and molecular risk stratification." PeerJ, 2023.
Pubmed: 37744220   DOI: 10.7717/peerj.16054

Nagasaka, Misako. et al. "Pan-tumor survey of RET fusions as detected by next-generation RNA sequencing identified RET fusion positive colorectal carcinoma as a unique molecular subset." Translational oncology, 2023.
RET fusions are considered driver alterations in cancer, which are often observed in non-small cell lung cancer and well-differentiated thyroid cancer. Though primarily seen in these two types of cancer, reports have also shown the presence of RET fusions in other solid tumors. This prominent genetic anomaly has been linked to tumor progression and is therefore a crucial target for therapeutic strategies. Further research on the role of RET fusion in various types of cancer may uncover potential treatment options. Within this context, RET fusion detection and management could potentially lead to improved clinical outcomes for these patients.
Nagasaka, Misako. et al. "Pan-tumor survey of RET fusions as detected by next-generation RNA sequencing identified RET fusion positive colorectal carcinoma as a unique molecular subset." Translational oncology, 2023.
Pubmed: 37516008   DOI: 10.1016/j.tranon.2023.101744